A coronavirus vaccine developed by the University of Oxford showed promising signs in making antibodies and triggering an immune response with patients.
The United Kingdom’s health secretary Matt Hancock in April said that the experimental vaccine was reported to have an 80% chance of working.
The trials involved 1,077 people. The researchers said however, that it is still too soon to know if this is enough to offer protection: “There is still much work to be done before we can confirm if our vaccine will help manage the Covid-19 pandemic, but these early results hold promise”, said Sarah Gilbert, a researcher in the project.
The vaccine is made from a genetically engineered virus that was made to resemble the coronavirus, but cannot cause infections in people. The study showed 90% of people developed antibodies after one dose. 10 people were given two doses so far, and all of them produced antibodies.
More than 10,000 people will take part in the next stage of the trials in the UK. There will be a trial involving 30,000 people in the United States, as well 2,000 in South Africa and 5,000 in Brazil.
Researchers have said that it is possible a vaccine will be proven effective before the end of the year, but, it will not be widely available.